Compare CTKB & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTKB | CADL |
|---|---|---|
| Founded | 1990 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 595.2M | 551.7M |
| IPO Year | 2021 | 2021 |
| Metric | CTKB | CADL |
|---|---|---|
| Price | $4.16 | $8.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $5.63 | ★ $19.00 |
| AVG Volume (30 Days) | 596.0K | ★ 2.0M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.62 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $193,015,000.00 | $125,000.00 |
| Revenue This Year | $5.42 | N/A |
| Revenue Next Year | $7.03 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.67 | N/A |
| 52 Week Low | $2.37 | $4.35 |
| 52 Week High | $6.18 | $8.36 |
| Indicator | CTKB | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 38.31 | 79.46 |
| Support Level | $4.00 | $4.80 |
| Resistance Level | $4.26 | N/A |
| Average True Range (ATR) | 0.27 | 0.54 |
| MACD | -0.02 | 0.19 |
| Stochastic Oscillator | 8.43 | 87.59 |
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.